Anavex Life Sciences is committed to advancing groundbreaking therapies for Alzheimer’s disease, Parkinson’s disease, and rare neurological disorders.
The Journal of Prevention of Alzheimer’s Disease (JPAD) has published peer-reviewed detailed results from the Phase IIb/III study evaluating oral blarcamesine (ANAVEX®2-73) for the treatment of early Alzheimer’s Disease (AD).
Orally administered ANAVEX®2-73 (blarcamesine) is an investigational small molecule being studied for its ability to enhance autophagy through SIGMAR1 activation, a receptor involved in restoring cellular homeostasis. Research is exploring its potential to address neurodegeneration by enhancing autophagy—a key cellular process that helps clear protein aggregates and misfolded proteins.
Currently under investigation in Phase IIb/III clinical trials to evaluate its safety and efficacy in early-stage Alzheimer’s.
Research includes a proof-of-concept study examining its potential benefits in Parkinson’s disease dementia.
Autophagy is the body’s natural way of clearing damaged proteins and cellular debris. In neurodegenerative diseases, this process can become impaired, leading to a buildup of toxic aggregates. Investigational therapies like blarcamesine aim to restore autophagy, offering a potential strategy for addressing these underlying disease mechanisms. Impaired autophagy processes are upstream of both amyloid beta and tau, and therefore anticipate the neurodegenerative process in Alzheimer’s disease.
Blarcamesine (ANAVEX®2-73) is an investigational oral therapy currently being studied for its potential to address conditions such as Alzheimer’s disease, Parkinson’s disease, and Rett syndrome. Research focuses on its ability to enhance autophagy through SIGMAR1 activation, a receptor that plays a key role in cellular processes related to neuroprotection and maintaining homeostasis.
Alzheimer’s Disease (AD) is a progressive and irreversible brain disorder that slowly erodes memory, cognitive abilities, and essential functions for independent living. It is the most common form of dementia and poses significant emotional, physical, and financial challenges for individuals and their families.
Parkinson’s Disease (PD) is a progressive neurological disorder that affects movement, balance, and coordination. It is primarily caused by the degeneration of dopamine-producing neurons in the brain, leading to motor symptoms such as tremors, stiffness, and slowed movement.
Rett Syndrome (RS) is a rare neurological disorder that primarily affects girls, causing severe cognitive, motor, and communication impairments. It is typically diagnosed in early childhood and is often marked by a loss of previously acquired skills.
Blarcamesine (ANAVEX®2-73) is an investigational drug. It is currently undergoing clinical trials and has not been approved by regulatory authorities. This information is intended for educational purposes only and does not suggest safety or efficacy conclusions.
Therapeutic Candidates
We are committed to advancing research into the underlying mechanisms of neurodegenerative and neurodevelopmental diseases. Our investigational therapies are designed to address these challenges through innovative approaches currently being evaluated in clinical trials.
An investigational therapy being studied for Alzheimer’s, Parkinson’s, and Rett syndrome.
Currently in preclinical evaluation for neurodegenerative conditions.
A preclinical-stage compound for central nervous system disorders.
Explore our presentations and engagements with the global scientific and investment communities.
